Results 81 to 90 of about 27,256 (249)

Vildagliptin and Omarigliptin Differentially Bind to DPP‐4 Homodimers and Modulate Osteoclast‐Mediated Bone Resorption

Comprehensive Physiology, Volume 16, Issue 1, February 2026.
Vildagliptin and omarigliptin, dipeptidyl peptidase‐4 (DPP‐4) inhibitors, have differential effects on bone cells. Although vildagliptin improved the bone microstructure of high‐fat diet‐fed rats, it was unable to downregulate osteoclastogenesis or the expression of key osteoclast transcripts.
Ratchaneevan Aeimlapa, Jiraporn Panmanee, Jarinthorn Teerapornpuntakit, Kannikar Wongdee, Jirawan Thongbunchoo, Nattapon Panupinthu, Saovaros Svasti, Nattayaporn Apaijai, Piangkwan Sa‐nguanmoo, Siriporn Chattipakorn, Nipon Chattipakorn, Narattaphol Charoenphandhu   +11 more
wiley   +1 more source

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin

Diabetes, Metabolic Syndrome and Obesity, 2010
Bo AhrénDepartment of Clinical Sciences, Lund University, Lund, SwedenAbstract: Inhibition of dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagonlike peptide-1 (GLP-1). This increases circulating levels of active GLP-1, stimulates
Ahren B
doaj   +2 more sources

Biocatalysis as Useful Tool in Asymmetric Synthesis: An Assessment of Recently Granted Patents (2014–2019) [PDF]

, 2019
The broad interdisciplinary nature of biocatalysis fosters innovation, as different technical fields are interconnected and synergized. A way to depict that innovation is by conducting a survey on patent activities.
Alcántara, Andrés R., Domínguez de María, Pablo, Gonzalo Calvo, Gonzalo de   +2 more
core   +3 more sources

Metabolic Outcomes in Patients With Type 2 Diabetes Prescribed Incretin‐Based Therapy and Referred or Not to a Weight Management Clinic: A Single‐Center Retrospective Analyses

Obesity Science &Practice, Volume 12, Issue 1, February 2026.
ABSTRACT Background Incretin therapies yield strong metabolic improvements, but whether adding a weight‐management (WM) clinic confers additional benefit beyond pharmacotherapy alone in routine care is unclear. Objective Evaluate whether referral to WM clinic, alongside standard diabetes care, provides additional benefit for adults with type 2 diabetes
Kathleen M. Robinson, Stephanie H. Rodriguez, Cyril Pedagarla, Patrick Ten Eyck, Marcelo Correia, Ayotunde Dokun   +5 more
wiley   +1 more source

Investigating operational stability and causes of cofactor release in fold type I amine transaminase

Protein Science, Volume 35, Issue 2, February 2026.
Abstract Amine transaminases (ATAs) are pyridoxal phosphate (PLP) dependent biocatalysts frequently employed in chiral amine synthesis. Yields of ATA‐catalyzed reactions often suffer from low enzyme operational stability due to weak interactions between the ATA and the aminated cofactor pyridoxamine phosphate (PMP), which can leak from the active site ...
Xuebin Feng, William Chau, Emma R. Master   +2 more
wiley   +1 more source

Prognostic Impact of DPP4 Inhibitors on Systemic Drug Therapy for Advanced Kidney Cancer Patients

Cancer Science, Volume 117, Issue 2, Page 468-475, February 2026.
Treatment with DPP4 inhibitors was identified as a favorable prognostic factor in patients with advanced RCC. A more substantial degree of tumor shrinkage was observed in the subgroup of patients who received tyrosine kinase inhibitors or immune checkpoint inhibitors as first‐line therapy.
Shuhei Kamada, Sachi Kitayama, Ryosuke Yamase, Kazuhiro Ikeda, Wataru Sato, Tomokazu Sazuka, Hideki Takeshita, Shinichi Sakamoto, Akihiro Yano, Kuniko Horie, Tomohiko Ichikawa, Satoru Kawakami, Satoshi Inoue   +12 more
wiley   +1 more source

Canagliflozin: A Review in Type 2 Diabetes. [PDF]

, 2017
peer reviewedCanagliflozin (Invokana(R)) is a sodium-glucose co-transporter-2 (SGLT2) inhibitor indicated in various countries worldwide for the once-daily oral treatment of type 2 diabetes (T2D).
Deeks, Emma D., Scheen, André
core   +2 more sources

Diabetes management in maternally inherited diabetes and deafness (MIDD): A review and a proposed treatment algorithm

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 826-839, February 2026.
Abstract Maternally inherited diabetes and deafness (MIDD) is a mitochondrial disorder usually caused by the variant m.3243A>G in the MT‐TL1 gene. We have proposed that diabetes in MIDD arises from a combination of insulin resistance and impaired β‐cell function that is more likely to occur in the presence of high skeletal muscle heteroplasmy and ...
Ahsen Chaudhry, David M. Thompson, Jean‐Pierre Chanoine   +2 more
wiley   +1 more source

Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors [PDF]

, 2009
BACKGROUND: Type 2 diabetes is a chronic, progressive disease with a multi-faceted pathophysiology. Beyond the known defects of insulin resistance and beta-cell insufficiency, derangement of incretin hormones normally produced from the gut wall in ...
Berneis, K, Rini, G B, Rizvi, A A, Rizzo, M, Spinas, G A   +4 more
core   +1 more source

Sodium glucose co‐transporter 2 inhibitors versus dipeptidyl peptidase‐4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population‐based cohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 935-945, February 2026.
Abstract Aims To determine whether sodium glucose co‐transporter 2 inhibitors (SGLT2i) use, compared with dipeptidyl peptidase‐4 inhibitors (DPP4i) use, is associated with the risk of ventricular arrhythmias (VA) among patients with type 2 diabetes. Materials and Methods We conducted a population‐based cohort study using a prevalent new‐user design and
Wang‐Choi Tang, Pauline Reynier, Antonios Douros, Oriana H. Y. Yu, Robert W. Platt, Kristian B. Filion   +5 more
wiley   +1 more source